Skip to main content
Caplight Logo









Expedition Therapeutics

Expedition Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://expeditiontx.com/

Last Round

Series B

Aug 5, 2026

Est. Valuation

$650M

Total Funding Raised

$280M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverytherapeutic candidatesbiotechclinical trialssmall-molecule inhibitorDPP1 inhibitorrespiratory diseaseCOPD treatmentdrug developmentbiopharmapreclinical developmentlicensing agreementmilestone paymentspharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Expedition Therapeutics Comparables

Compare Expedition Therapeutics with similar companies based on industry and business-model similarity.

Expedition Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Coultreon Biopharma
74%
GSK plc
72%
Slate Medicines
71%

Expedition Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 5, 2026
Series AOct 9, 2025

Key People

Founding team and executive leadership

Yi Larson

President and CEO

Executive Team

Expedition Therapeutics Investors

Notable investors and investment history

Expedition Therapeutics investors
InvestorRounds
Balyasny Asset Management L.P.Series A, Series B
RA Capital ManagementSeries B
Lake Bleu CapitalSeries A
ForbionSeries A, Series B
Logos CapitalSeries A, Series B
Novo HoldingsSeries B, Series A
BVF Partners L.P.Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 5, 2026

    $115M round led by General Atlantic.

  • Jul 25, 2026

    Monthly visitors increased 32% MoM.

Expedition Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Expedition Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Expedition Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range14
Year Founded2024
Last FundingAug 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?